141 related articles for article (PubMed ID: 21272954)
1. Lung cancer in never smokers: change of a mindset in the molecular era.
Lee YJ; Kim JH; Kim SK; Ha SJ; Mok TS; Mitsudomi T; Cho BC
Lung Cancer; 2011 Apr; 72(1):9-15. PubMed ID: 21272954
[TBL] [Abstract][Full Text] [Related]
2. Lung cancer in never smokers: a review.
Subramanian J; Govindan R
J Clin Oncol; 2007 Feb; 25(5):561-70. PubMed ID: 17290066
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications.
Prudkin L; Wistuba II
Ann Diagn Pathol; 2006 Oct; 10(5):306-15. PubMed ID: 16979526
[TBL] [Abstract][Full Text] [Related]
4. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.
Bonomi PD; Buckingham L; Coon J
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4606-12. PubMed ID: 17671150
[TBL] [Abstract][Full Text] [Related]
5. Lung cancer in never smokers.
Torok S; Hegedus B; Laszlo V; Hoda MA; Ghanim B; Berger W; Klepetko W; Dome B; Ostoros G
Future Oncol; 2011 Oct; 7(10):1195-211. PubMed ID: 21992731
[TBL] [Abstract][Full Text] [Related]
6. Impact of environmental tobacco smoke on the incidence of mutations in epidermal growth factor receptor gene in never-smoker patients with non-small-cell lung cancer.
Lee YJ; Cho BC; Jee SH; Moon JW; Kim SK; Chang J; Chung KY; Park IK; Choi SH; Kim JH
J Clin Oncol; 2010 Jan; 28(3):487-92. PubMed ID: 20008630
[TBL] [Abstract][Full Text] [Related]
7. Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors.
Toschi L; Cappuzzo F
Oncologist; 2007 Feb; 12(2):211-20. PubMed ID: 17296817
[TBL] [Abstract][Full Text] [Related]
8. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
John T; Liu G; Tsao MS
Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
[TBL] [Abstract][Full Text] [Related]
9. Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers.
Chapman AM; Sun KY; Ruestow P; Cowan DM; Madl AK
Lung Cancer; 2016 Dec; 102():122-134. PubMed ID: 27987580
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor mutations in small cell lung cancer.
Tatematsu A; Shimizu J; Murakami Y; Horio Y; Nakamura S; Hida T; Mitsudomi T; Yatabe Y
Clin Cancer Res; 2008 Oct; 14(19):6092-6. PubMed ID: 18829487
[TBL] [Abstract][Full Text] [Related]
11. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Jänne PA; Johnson BE
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
[TBL] [Abstract][Full Text] [Related]
12. First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?
Gridelli C
Curr Opin Oncol; 2011 Mar; 23(2):131-2. PubMed ID: 21307676
[No Abstract] [Full Text] [Related]
13. Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status.
Pesek M; Benesova L; Belsanova B; Mukensnabl P; Bruha F; Minarik M
Anticancer Res; 2009 Jul; 29(7):2767-73. PubMed ID: 19596959
[TBL] [Abstract][Full Text] [Related]
14. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.
Mounawar M; Mukeria A; Le Calvez F; Hung RJ; Renard H; Cortot A; Bollart C; Zaridze D; Brennan P; Boffetta P; Brambilla E; Hainaut P
Cancer Res; 2007 Jun; 67(12):5667-72. PubMed ID: 17575133
[TBL] [Abstract][Full Text] [Related]
15. Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer.
Batus M; Fidler MJ; Bonomi PD
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1589-99. PubMed ID: 20942630
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors.
Cohen V; Agulnik JS; Ang C; Kasymjanova G; Batist G; Small D; Brandao G; Chong G; Miller WH
Cancer; 2010 Sep; 116(18):4309-17. PubMed ID: 20549828
[TBL] [Abstract][Full Text] [Related]
17. Personalized medicine for non-small-cell lung cancer.
Mok TS; Zhou Q; Leung L; Loong HH
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1601-11. PubMed ID: 20942631
[TBL] [Abstract][Full Text] [Related]
18. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors.
Calvo E; Baselga J
J Clin Oncol; 2006 May; 24(14):2158-63. PubMed ID: 16682734
[TBL] [Abstract][Full Text] [Related]
19. Lung cancer in 'Never-smokers': a unique entity.
Subramanian J; Govindan R
Oncology (Williston Park); 2010 Jan; 24(1):29-35. PubMed ID: 20187318
[TBL] [Abstract][Full Text] [Related]
20. Molecular genetics of lung cancer in people who have never smoked.
Subramanian J; Govindan R
Lancet Oncol; 2008 Jul; 9(7):676-82. PubMed ID: 18598932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
